We are live on ! Find out more
PRPO icon

Precipio

26.44 USD
-0.22
0.83%
At close Updated Sep 17, 4:00 PM EDT
1 day
-0.83%
5 days
-2.18%
1 month
10.63%
3 months
18.25%
6 months
-9.91%
Year to date
11%
1 year
50.66%
5 years
-57.49%
10 years
-99.02%
 

About: Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

Employees: 71

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 50%
Neutral 50%
Negative 0%
Positive
Zacks Investment Research
24 days ago
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Positive
Zacks Investment Research
27 days ago
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
Neutral
Seeking Alpha
1 month ago
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Precipio Announces Q2-2026 Financial Results
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
Precipio Announces Q2-2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
Precipio Announces Q2-2026 Shareholder Update Call
NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.   (NASDAQ: PRPO) , will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET.
Precipio Announces Q2-2026 Shareholder Update Call
Positive
Zacks Investment Research
2 months ago
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Neutral
GlobeNewsWire
3 months ago
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Neutral
GlobeNewsWire
3 months ago
Precipio to Present at the Planet MicroCap Las Vegas
NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc. (NASDAQ: PRPO) , announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion.
Precipio to Present at the Planet MicroCap Las Vegas
Neutral
Zacks Investment Research
3 months ago
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
Neutral
Seeking Alpha
4 months ago
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™